{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:04:47Z","timestamp":1791515087227,"version":"4.3.4"},"reference-count":101,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Manistee"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","award":["ASPIRE grant 86920041"],"award-info":[{"award-number":["ASPIRE grant 86920041"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Satsuma"},{"name":"Tonix"},{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"crossref","award":["Vici Grant 09150181910040"],"award-info":[{"award-number":["Vici Grant 09150181910040"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001826","name":"The Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","award":["849200007"],"award-info":[{"award-number":["849200007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Cardiovascular modulation mediated by adenine-based purines is a very complicated and dynamic process driven by adenosine, adenosine diphosphate (ADP), and adenosine triphosphate (ATP). It is orchestrated through the interaction of these molecules with specific purinergic P1, P2Y, and P2X receptors, located throughout the central and peripheral nervous systems. This, along with the constant enzymatic interconversion of these compounds by ectonucleotidases, results in overlapping and highly variable cardiovascular responses. Activation of G protein-coupled purinergic P2Y receptors plays a fundamental role in cardiovascular homeostasis, modulating autonomic integration, neurogenic transmission, and vascular function. Within this context, ADP-sensitive P2Y receptors, particularly the P2Y1, P2Y12, and P2Y13 subtypes, participate in distinct sensory, autonomic, and functional cardiovascular mechanisms, as identified in several in vitro and in vivo experimental models. Accordingly: (i) the stable and non-hydrolysable ADP analogue, adenosine 5\u2032-O-(\u03b2-thio)-diphosphate (ADP\u03b2S), has been widely used as a pharmacological tool to investigate P2Y receptor-mediated cardiovascular responses; and (ii) the specific role of P2Y receptors has been confirmed using selective P2Y receptor antagonists, including MRS2500 (P2Y1), PSB0739 (P2Y12) or MRS2211 (P2Y13). The cardiovascular effects of ADP are complex; depending on the experimental conditions, it can either decrease or increase heart rate, myocardial contractility, vascular tone, and\/or systemic blood pressure. These effects are mediated by several P2Y receptors that act at different levels of cardiovascular control, encompassing crucial integration sites within the central nervous system, as well as peripheral autonomic and cardiovascular effector mechanisms such as preganglionic nerves, autonomic ganglia, postganglionic nerves, sensory fibres, vascular smooth muscle, vascular endothelium, and cardiac tissues. In this review, we: (i) summarize the pharmacological profile of the P2Y receptors that mediate cardiovascular responses, with special emphasis on peripheral autonomic, sensory, and vascular mechanisms, revealed in in vivo experimental models; and (ii) highlight the potential of P2Y receptors as therapeutic targets for the treatment of cardiovascular pathologies, including hypertension, coronary vasospasm, ischemic injury, and coagulation problems.<\/jats:p>","DOI":"10.31083\/jin51224","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:51:46Z","timestamp":1788439906000},"source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological Profile of Purinergic P2Y Receptors Involved in Neurogenic Cardiovascular Modulation Induced by ADP and Related Compounds in Rats"],"prefix":"10.31083","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8616-4820","authenticated-orcid":true,"given":"Roberto C.","family":"Silva-Velasco","sequence":"first","affiliation":[{"name":"Department of Pharmacobiology, Cinvestav-Coapa, 14330 Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5182-8957","authenticated-orcid":true,"given":"Kristian A.","family":"Haanes","sequence":"additional","affiliation":[{"name":"Translational Research Centre, Copenhagen University Hospital \u2013 Rigshospitalet, 2600 Glostrup, Denmark"},{"name":"Department of Health Technology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark"},{"name":"Department of Biology, University of Copenhagen, 2200 Copenhagen, Denmark"},{"name":"Danish Headache Center, Department of Neurology, Copenhagen University Hospital \u2013 Rigshospitalet, 2600 Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3516-8885","authenticated-orcid":true,"given":"Belinda","family":"Villanueva-Castillo","sequence":"additional","affiliation":[{"name":"Department of Pharmacobiology, Cinvestav-Coapa, 14330 Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7176-126X","authenticated-orcid":true,"given":"Antoinette","family":"Maassen van den Brink","sequence":"additional","affiliation":[{"name":"Division of Vascular Medicine and Pharmacology, Erasmus MC University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4117-1343","authenticated-orcid":true,"given":"Carlos M.","family":"Villal\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Pharmacobiology, Cinvestav-Coapa, 14330 Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Burnstock G. Purinergic signalling in the cardiovascular system. Circulation Research. 2017; 120: 207\u2013228.","DOI":"10.1161\/CIRCRESAHA.116.309726"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Erb L, Weisman GA. Coupling of P2Y receptors to G proteins and other signaling pathways. Wiley Interdisciplinary Reviews. Membrane Transport and Signaling. 2012; 1: 789\u2013803.","DOI":"10.1002\/wmts.62"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Lazarowski ER. Vesicular and conductive mechanisms of nucleotide release. Purinergic Signalling. 2012; 8: 359\u2013373.","DOI":"10.1007\/s11302-012-9304-9"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Jacobson KA, Delicado EG, Gachet C, Kennedy C, von K\u00fcgelgen I, Li B, et al. Update of P2Y receptor pharmacology: IUPHAR Review 27. British Journal of Pharmacology. 2020; 177: 2413\u20132433.","DOI":"10.1111\/bph.15005"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"von K\u00fcgelgen I. Pharmacology of P2Y receptors. Brain Research Bulletin. 2019; 151: 12\u201324.","DOI":"10.1016\/j.brainresbull.2019.03.010"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacology & Therapeutics. 1994; 64: 445\u2013475.","DOI":"10.1016\/0163-7258(94)00048-4"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Li Q, Olesky M, Palmer RK, Harden TK, Nicholas RA. Evidence that the p2y3 receptor is the avian homologue of the mammalian P2Y6 receptor. Molecular Pharmacology. 1998; 54: 541\u2013546.","DOI":"10.1124\/mol.54.3.541"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Burnstock G. Purine and pyrimidine receptors. Cellular and Molecular Life Sciences: CMLS. 2007; 64: 1471\u20131483.","DOI":"10.1007\/s00018-007-6497-0"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Burnstock G. Purinergic Signalling: Therapeutic Developments. Frontiers in Pharmacology. 2017; 8: 661.","DOI":"10.3389\/fphar.2017.00661"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Burnstock G, Ralevic V. Purinergic signaling and blood vessels in health and disease. Pharmacological Reviews. 2013; 66: 102\u2013192.","DOI":"10.1124\/pr.113.008029"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"von K\u00fcgelgen I, N\u00f6renberg W, Koch H, Meyer A, Illes P, Starke K. P2-receptors controlling neurotransmitter release from postganglionic sympathetic neurones. Progress in Brain Research. 1999; 120: 173\u2013182.","DOI":"10.1016\/s0079-6123(08)63554-2"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Nishimura A, Sunggip C, Oda S, Numaga-Tomita T, Tsuda M, Nishida M. Purinergic P2Y receptors: Molecular diversity and implications for treatment of cardiovascular diseases. Pharmacology & Therapeutics. 2017; 180: 113\u2013128.","DOI":"10.1016\/j.pharmthera.2017.06.010"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacological Reviews. 2006; 58: 281\u2013341.","DOI":"10.1124\/pr.58.3.3"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Villanueva-Castillo B, Rivera-Mancilla E, Haanes KA, MaassenVanDenBrink A, Villal\u00f3n CM. The role of purinergic P2Y12 and P2Y13 receptors in ADP\u03b2S-induced inhibition of the cardioaccelerator sympathetic drive in pithed rats. Purinergic Signalling. 2020; 16: 73\u201384.","DOI":"10.1007\/s11302-020-09689-z"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Haanes KA, Labastida-Ram\u00edrez A, Blixt FW, Rubio-Beltr\u00e1n E, Dirven CM, Danser AH, et al. Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models. Cephalalgia: an International Journal of Headache. 2019; 39: 1421\u20131434.","DOI":"10.1177\/0333102419851810"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Miguel-Mart\u00ednez AD, Linares-Bedolla J, Villanueva-Castillo B, Haanes KA, MaassenVanDenBrink A, Villal\u00f3n CM. Pharmacological Profile of the Purinergic P2Y Receptors That Modulate, in Response to ADP\u03b2S, the Vasodepressor Sensory CGRPergic Outflow in Pithed Rats. Pharmaceuticals (Basel, Switzerland). 2023; 16: 475.","DOI":"10.3390\/ph16030475"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Burnstock G, Fredholm BB, Verkhratsky A. Adenosine and ATP receptors in the brain. Current Topics in Medicinal Chemistry. 2011; 11: 973\u20131011.","DOI":"10.2174\/156802611795347627"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signalling. 2008; 4: 1\u201320.","DOI":"10.1007\/s11302-007-9078-7"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacological Reviews. 1998; 50: 413\u2013492.","DOI":"10.1016\/S0031-6997(24)01373-5"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Reiss AB, Grossfeld D, Kasselman LJ, Renna HA, Vernice NA, Drewes W, et al. Adenosine and the Cardiovascular System. American Journal of Cardiovascular Drugs: Drugs, Devices, and other Interventions. 2019; 19: 449\u2013464.","DOI":"10.1007\/s40256-019-00345-5"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Villal\u00f3n CM, Centuri\u00f3n D, del Mar Fern\u00e1ndez M, Mor\u00e1n A, S\u00e1nchez-L\u00f3pez A. 5-Hydroxytryptamine inhibits the tachycardia induced by selective preganglionic sympathetic stimulation in pithed rats. Life Sciences. 1999; 64: 1839\u20131847.","DOI":"10.1016\/s0024-3205(99)00126-5"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Silva-Velasco RC, Villanueva-Castillo B, Haanes KA, MaassenVanDenBrink A, Villal\u00f3n CM. Pharmacological Nature of the Purinergic P2Y Receptor Subtypes That Participate in the Blood Pressure Changes Produced by ADP\u03b2S in Rats. Pharmaceuticals (Basel, Switzerland). 2023; 16: 1683.","DOI":"10.3390\/ph16121683"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Avil\u00e9s-Rosas VH, Rivera-Mancilla E, Marichal-Cancino BA, Manrique-Maldonado G, Altamirano-Espinoza AH, Maassen Van Den Brink A, et al. Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats. British Journal of Pharmacology. 2017; 174: 2001\u20132014.","DOI":"10.1111\/bph.13799"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"de Paula PM, Antunes VR, Bonagamba LGH, Machado BH. Cardiovascular responses to microinjection of ATP into the nucleus tractus solitarii of awake rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2004; 287: R1164\u201371.","DOI":"10.1152\/ajpregu.00722.2003"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Wenker IC, Sobrinho CR, Takakura AC, Mulkey DK, Moreira TS. P2Y1 receptors expressed by C1 neurons determine peripheral chemoreceptor modulation of breathing, sympathetic activity, and blood pressure. Hypertension (Dallas, Tex.: 1979). 2013; 62: 263\u2013273.","DOI":"10.1161\/HYPERTENSIONAHA.113.01487"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Buvinic S, Briones R, Huidobro-Toro JP. P2Y(1) and P2Y(2) receptors are coupled to the NO\/cGMP pathway to vasodilate the rat arterial mesenteric bed. British Journal of Pharmacology. 2002; 136: 847\u2013856.","DOI":"10.1038\/sj.bjp.0704789"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Fong AY, Krstew EV, Barden JA, Lawrence AJ. Immunoreactive localisation of P2Y1 receptors within the rat and human nodose ganglia and rat brainstem: Comparison with [\u03b133P]deoxyadenosine 5\u2019-triphosphate autoradiography. Neuroscience. 2002; 113: 809\u2013823.","DOI":"10.1016\/S0306-4522(02)00237-3"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Maesawa S, Yokoyama T, Sakanoue W, Yamamoto Y, Hirakawa M, Shiraishi H, et al. ADP-mediated Modulation of Intracellular Calcium Responses in Chromaffin Cells: The Role of Ectonucleoside Triphosphate Diphosphohydrolase 2 on Rat Adrenal Medulla Function. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society. 2024; 72: 41\u201360.","DOI":"10.1369\/00221554231221872"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Molliver DC, Cook SP, Carlsten JA, Wright DE, McCleskey EW. ATP and UTP excite sensory neurons and induce CREB phosphorylation through the metabotropic receptor, P2Y2. The European Journal of Neuroscience. 2002; 16: 1850\u20131860.","DOI":"10.1046\/j.1460-9568.2002.02253.x"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Dales MO, Mitchell C, Gurney AM, Drummond RM, Kennedy C. Characterisation of P2Y receptor subtypes mediating vasodilation and vasoconstriction of rat pulmonary artery using selective antagonists. Purinergic Signalling. 2022; 18: 515\u2013528.","DOI":"10.1007\/s11302-022-09895-x"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Braga VA, Soriano RN, Braccialli AL, de Paula PM, Bonagamba LGH, Paton JFR, et al. Involvement of L-glutamate and ATP in the neurotransmission of the sympathoexcitatory component of the chemoreflex in the commissural nucleus tractus solitarii of awake rats and in the working heart-brainstem preparation. The Journal of Physiology. 2007; 581: 1129\u20131145.","DOI":"10.1113\/jphysiol.2007.129031"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Burnstock G. Purinergic signalling. British Journal of Pharmacology. 2006; 147 Suppl 1: S172\u201381.","DOI":"10.1038\/sj.bjp.0706429"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Bou\u00e9-Grabot E, Pankratov Y. Modulation of Central Synapses by Astrocyte-Released ATP and Postsynaptic P2X Receptors. Neural Plasticity. 2017; 2017: 9454275.","DOI":"10.1155\/2017\/9454275"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiology of Disease. 2010; 37: 13\u201325.","DOI":"10.1016\/j.nbd.2009.07.030"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Biancardi VC, Son SJ, Ahmadi S, Filosa JA, Stern JE. Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier. Hypertension (Dallas, Tex.: 1979). 2014; 63: 572\u2013579.","DOI":"10.1161\/HYPERTENSIONAHA.113.01743"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiology of Disease. 2008; 32: 200\u2013219.","DOI":"10.1016\/j.nbd.2008.08.005"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Evans RJ, Derkach V, Surprenant A. ATP mediates fast synaptic transmission in mammalian neurons. Nature. 1992; 357: 503\u2013505.","DOI":"10.1038\/357503a0"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Galligan JJ, Bertrand PP. ATP mediates fast synaptic potentials in enteric neurons. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 1994; 14: 7563\u20137571.","DOI":"10.1523\/JNEUROSCI.14-12-07563.1994"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Abbracchio MP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: an overview. Trends in Neurosciences. 2009; 32: 19\u201329.","DOI":"10.1016\/j.tins.2008.10.001"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Shigetomi E, Sakai K, Koizumi S. Extracellular ATP\/adenosine dynamics in the brain and its role in health and disease. Frontiers in Cell and Developmental Biology. 2024; 11: 1343653.","DOI":"10.3389\/fcell.2023.1343653"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Barraco RA, el-Ridi MR, Ergene E, Phillis JW. Adenosine receptor subtypes in the brainstem mediate distinct cardiovascular response patterns. Brain Research Bulletin. 1991; 26: 59\u201384.","DOI":"10.1016\/0361-9230(91)90192-m"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Kennedy C. ATP as a cotransmitter in the autonomic nervous system. Autonomic Neuroscience: Basic & Clinical. 2015; 191: 2\u201315.","DOI":"10.1016\/j.autneu.2015.04.004"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Coote JH, Yang Z, Pyner S, Deering J. Control of sympathetic outflows by the hypothalamic paraventricular nucleus. Clinical and Experimental Pharmacology & Physiology. 1998; 25: 461\u2013463.","DOI":"10.1111\/j.1440-1681.1998.tb02235.x"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Cruz JC, Bonagamba LGH, Machado BH. Modulation of arterial pressure by P2 purinoceptors in the paraventricular nucleus of the hypothalamus of awake rats. Autonomic Neuroscience: Basic & Clinical. 2010; 158: 79\u201385.","DOI":"10.1016\/j.autneu.2010.06.012"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Ferreira-Neto HC, Yao ST, Antunes VR. Purinergic and glutamatergic interactions in the hypothalamic paraventricular nucleus modulate sympathetic outflow. Purinergic Signalling. 2013; 9: 337\u2013349.","DOI":"10.1007\/s11302-013-9352-9"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Burnstock G. Purinergic signalling: from discovery to current developments. Experimental Physiology. 2014; 99: 16\u201334.","DOI":"10.1113\/expphysiol.2013.071951"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Kapoor JR, Sladek CD. Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2000; 20: 8868\u20138875.","DOI":"10.1523\/JNEUROSCI.20-23-08868.2000"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Mori M, Tsushima H, Matsuda T. Antidiuretic effects of purinoceptor agonists injected into the hypothalamic paraventricular nucleus of water-loaded, ethanol-anesthetized rats. Neuropharmacology. 1992; 31: 585\u2013592.","DOI":"10.1016\/0028-3908(92)90191-q"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Kubo T, Yanagihara Y, Yamaguchi H, Fukumori R. Excitatory amino acid receptors in the paraventricular hypothalamic nucleus mediate pressor response induced by carotid body chemoreceptor stimulation in rats. Clinical and Experimental Hypertension (New York, N.Y.: 1993). 1997; 19: 1117\u20131134.","DOI":"10.3109\/10641969709083208"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Dampney RA. Functional organization of central pathways regulating the cardiovascular system. Physiological Reviews. 1994; 74: 323\u2013364.","DOI":"10.1152\/physrev.1994.74.2.323"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Marina N, Tang F, Figueiredo M, Mastitskaya S, Kasimov V, Mohamed-Ali V, et al. Purinergic signalling in the rostral ventro-lateral medulla controls sympathetic drive and contributes to the progression of heart failure following myocardial infarction in rats. Basic Research in Cardiology. 2013; 108: 317.","DOI":"10.1007\/s00395-012-0317-x"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Ralevic V. Purinergic signalling in the cardiovascular system-a tribute to Geoffrey Burnstock. Purinergic Signalling. 2021; 17: 63\u201369.","DOI":"10.1007\/s11302-020-09734-x"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Fisher LA, Brown MR. Neuropeptides and the autonomic nervous system. Psychotherapy and Psychosomatics. 1993; 60: 39\u201345.","DOI":"10.1159\/000288678"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Burnstock G. Cotransmission. Current Opinion in Pharmacology. 2004; 4: 47\u201352.","DOI":"10.1016\/j.coph.2003.08.001"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Ueno H, Sano M, Hara M, Noji H. Digital Cascade Assays for ADP- or ATP-Producing Enzymes Using a Femtoliter Reactor Array Device. ACS Sensors. 2023; 8: 3400\u20133407.","DOI":"10.1021\/acssensors.3c00587"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Marichal-Cancino BA, Gonz\u00e1lez-Hern\u00e1ndez A, Mu\u00f1oz-Islas E, Villal\u00f3n CM. Monoaminergic Receptors as Modulators of the Perivascular Sympathetic and Sensory CGRPergic Outflows. Current Neuropharmacology. 2020; 18: 790\u2013808.","DOI":"10.2174\/1570159X18666200503223240"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Taguchi T, Kawasaki H, Imamura T, Takasaki K. Endogenous calcitonin gene-related peptide mediates nonadrenergic noncholinergic depressor response to spinal cord stimulation in the pithed rat. Circulation Research. 1992; 71: 357\u2013364.","DOI":"10.1161\/01.res.71.2.357"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001; 413: 203\u2013210.","DOI":"10.1038\/35093019"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neuroscience and Biobehavioral Reviews. 1997; 21: 649\u2013678.","DOI":"10.1016\/s0149-7634(96)00023-1"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Brashear RE, Mandelbaum I, Ross JC. Selected cardiovascular effects of adenosine diphosphate. American Heart Journal. 1970; 80: 63\u201369.","DOI":"10.1016\/0002-8703(70)90038-4"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, et al. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduction and Targeted Therapy. 2021; 6: 162.","DOI":"10.1038\/s41392-021-00553-z"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Haanes KA, Edvinsson L. Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets. CNS Drugs. 2019; 33: 525\u2013537.","DOI":"10.1007\/s40263-019-00630-6"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Ralevic V. Purines as neurotransmitters and neuromodulators in blood vessels. Current Vascular Pharmacology. 2009; 7: 3\u201314.","DOI":"10.2174\/157016109787354123"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Burnstock G. Purinergic nerves. Pharmacological Reviews. 1972; 24: 509\u2013581.","DOI":"10.1016\/S0031-6997(25)06930-3"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Ralevic V, Burnstock G. Roles of P2-purinoceptors in the cardiovascular system. Circulation. 1991; 84: 1\u201314.","DOI":"10.1161\/01.cir.84.1.1"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Dejana E, de Gaetano G, Bonaccorsi A. Role of the lung in the development of cardiovascular modifications during ADP infusion in the rat. Thrombosis Research. 1978; 12: 47\u201357.","DOI":"10.1016\/0049-3848(78)90084-1"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Shipley RE, Tilden JH. A pithed rat preparation suitable for assaying pressor substances. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 1947; 64: 453\u2013455.","DOI":"10.3181\/00379727-64-15828"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Hansmann G, Ihling C, Pieske B, B\u00fcltmann R. Nucleotide-evoked relaxation of human coronary artery. European Journal of Pharmacology. 1998; 359: 59\u201367.","DOI":"10.1016\/s0014-2999(98)00572-x"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Villal\u00f3n CM, Albarr\u00e1n-Ju\u00e1rez JA, Lozano-Cuenca J, Pertz HH, G\u00f6rnemann T, Centuri\u00f3n D. Pharmacological profile of the clonidine-induced inhibition of vasodepressor sensory outflow in pithed rats: correlation with alpha(2A\/2C)-adrenoceptors. British Journal of Pharmacology. 2008; 154: 51\u201359.","DOI":"10.1038\/bjp.2008.49"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985; 313: 54\u201356.","DOI":"10.1038\/313054a0"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiological Reviews. 2014; 94: 1099\u20131142.","DOI":"10.1152\/physrev.00034.2013"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual Review of Pharmacology and Toxicology. 2015; 55: 533\u2013552.","DOI":"10.1146\/annurev-pharmtox-010814-124701"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Zimmermann K, Reeh PW, Averbeck B. ATP can enhance the proton-induced CGRP release through P2Y receptors and secondary PGE(2) release in isolated rat dura mater. Pain. 2002; 97: 259\u2013265.","DOI":"10.1016\/S0304-3959(02)00027-1"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Jacobson KA, M\u00fcller CE. Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharmacology. 2016; 104: 31\u201349.","DOI":"10.1016\/j.neuropharm.2015.12.001"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"von K\u00fcgelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacology & Therapeutics. 2006; 110: 415\u2013432.","DOI":"10.1016\/j.pharmthera.2005.08.014"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Douglas WW, Rubin RP. The role of calcium in the secretory response of the adrenal medulla to acetylcholine. The Journal of Physiology. 1961; 159: 40\u201357.","DOI":"10.1113\/jphysiol.1961.sp006791"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Neher E, Marty A. Discrete changes of cell membrane capacitance observed under conditions of enhanced secretion in bovine adrenal chromaffin cells. Proceedings of the National Academy of Sciences of the United States of America. 1982; 79: 6712\u20136716.","DOI":"10.1073\/pnas.79.21.6712"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Burnstock G, Novak I. Purinergic signalling in the pancreas in health and disease. The Journal of Endocrinology. 2012; 213: 123\u2013141.","DOI":"10.1530\/JOE-11-0434"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Rodrigues RJ, Tom\u00e9 AR, Cunha RA. ATP as a multi-target danger signal in the brain. Frontiers in Neuroscience. 2015; 9: 148.","DOI":"10.3389\/fnins.2015.00148"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Powell AD, Teschemacher AG, Seward EP. P2Y purinoceptors inhibit exocytosis in adrenal chromaffin cells via modulation of voltage-operated calcium channels. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience. 2000; 20: 606\u2013616.","DOI":"10.1523\/JNEUROSCI.20-02-00606.2000"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Villal\u00f3n CM, Centuri\u00f3n D. Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors\/mechanisms involved and therapeutic implications. Naunyn-Schmiedeberg's Archives of Pharmacology. 2007; 376: 45\u201363.","DOI":"10.1007\/s00210-007-0179-1"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Cabou C, Martinez LO. The Interplay of Endothelial P2Y Receptors in Cardiovascular Health: From Vascular Physiology to Pathology. International Journal of Molecular Sciences. 2022; 23: 5883.","DOI":"10.3390\/ijms23115883"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Guo Y, Mao T, Fang Y, Wang H, Yu J, Zhu Y, et al. Comprehensive insights into potential roles of purinergic P2 receptors on diseases: Signaling pathways involved and potential therapeutics. Journal of Advanced Research. 2025; 69: 427\u2013448.","DOI":"10.1016\/j.jare.2024.03.027"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Kiaie SH, Hatami Z, Nasr MS, Pazooki P, Hemmati S, Baradaran B, et al. Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation. Purinergic Signalling. 2024; 20: 321\u2013343.","DOI":"10.1007\/s11302-023-09966-7"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Strassheim D, Verin A, Batori R, Nijmeh H, Burns N, Kovacs-Kasa A, et al. P2Y Purinergic Receptors, Endothelial Dysfunction, and Cardiovascular Diseases. International Journal of Molecular Sciences. 2020; 21: 6855.","DOI":"10.3390\/ijms21186855"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Kishore SP, Blank E, Heller DJ, Patel A, Peters A, Price M, et al. Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases. Journal of the American College of Cardiology. 2018; 71: 564\u2013574.","DOI":"10.1016\/j.jacc.2017.11.056"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Sch\u00fcpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, W\u00f6hrle J, et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. The New England Journal of Medicine. 2019; 381: 1524\u20131534.","DOI":"10.1056\/NEJMoa1908973"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Angiolillo DJ, Ferreiro JL. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Revista Espanola De Cardiologia. 2010; 63: 60\u201376.","DOI":"10.1016\/s1885-5857(10)70010-4"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Baqi Y, M\u00fcller CE. Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery. Drug Discovery Today. 2019; 24: 325\u2013333.","DOI":"10.1016\/j.drudis.2018.09.021"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Chen XY, Wang K, Jia J, Kong XT, Li HQ, Tian S. P2Y12R antagonists in antithrombotic therapy: a patent and literature review (2019-present). Expert Opinion on Therapeutic Patents. 2025; 35: 515\u2013532.","DOI":"10.1080\/13543776.2025.2467683"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Burnstock G, Kennedy C. P2X receptors in health and disease. Advances in Pharmacology (San Diego, Calif.). 2011; 61: 333\u2013372.","DOI":"10.1016\/B978-0-12-385526-8.00011-4"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Burnstock G, Pelleg A. Cardiac purinergic signalling in health and disease. Purinergic Signalling. 2015; 11: 1\u201346.","DOI":"10.1007\/s11302-014-9436-1"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Gourine AV, Llaudet E, Dale N, Spyer KM. ATP is a mediator of chemosensory transduction in the central nervous system. Nature. 2005; 436: 108\u2013111.","DOI":"10.1038\/nature03690"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Cattaneo M. P2Y12 receptors: structure and function. Journal of Thrombosis and Haemostasis: JTH. 2015; 13 Suppl 1: S10\u20136.","DOI":"10.1111\/jth.12952"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJJ, Jonasson J, Nylander S, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. Journal of the American College of Cardiology. 2013; 61: 723\u2013727.","DOI":"10.1016\/j.jacc.2012.11.032"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Favre J, Roy C, Guihot AL, Drouin A, Laprise M, Gillis MA, et al. NTPDase1\/CD39 Ectonucleotidase Is Necessary for Normal Arterial Diameter Adaptation to Flow. International Journal of Molecular Sciences. 2023; 24: 15038.","DOI":"10.3390\/ijms242015038"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, \u00c5d\u00e9n U, et al. Adenosine receptor signaling in vitro and in vivo. Drug Development Research. 2001; 52: 274\u2013282.","DOI":"10.1002\/ddr.1124"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Burnstock G, Knight GE. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signalling. 2018; 14: 1\u201318.","DOI":"10.1007\/s11302-017-9593-0"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Burnstock G, Verkhratsky A. Purinergic Signalling and the Nervous System. Heidelberg: Springer. 2012.","DOI":"10.1007\/978-3-642-28863-0"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opinion on Therapeutic Targets. 2020; 24: 91\u2013100.","DOI":"10.1080\/14728222.2020.1724285"},{"key":"ref101","doi-asserted-by":"publisher","unstructured":"Haanes KA, Spray S, Syberg S, J\u00f8rgensen NR, Robaye B, Boeynaems JM, et al. New insights on pyrimidine signalling within the arterial vasculature - Different roles for P2Y2 and P2Y6 receptors in large and small coronary arteries of the mouse. Journal of Molecular and Cellular Cardiology. 2016; 93: 1\u201311.","DOI":"10.1016\/j.yjmcc.2016.01.025"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/25\/8\/10.31083\/JIN51224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:52:25Z","timestamp":1788439945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/25\/8\/10.31083\/JIN51224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":101,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"alternative-id":["S0219-6352(26)01169-1"],"URL":"https:\/\/doi.org\/10.31083\/jin51224","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"51224"}}